Who are Etoricoxib (Arcoxia)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Parecoxib and Celecoxib, Parestat(generic parecoxib), Parecoxib Sodium/Valdecoxib, Celecoxib 400 milligrams, parecoxib, valdecoxib, parecoxib and dexamethasone, Celecoxib (Celebrex).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etoricoxib-arcoxia.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Etoricoxib (Arcoxia) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Etoricoxib (Arcoxia) (Etoricoxib (Arcoxia)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective COX-2 inhibitor (coxib). Area: Rheumatology / Pain Management.

marketed Selective COX-2 inhibitor (coxib) COX-2 (Cyclooxygenase-2) Rheumatology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Etoricoxib (Arcoxia) (Etoricoxib (Arcoxia)) — Radboud University Medical Center. Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Etoricoxib (Arcoxia) TARGET	Etoricoxib (Arcoxia)	Radboud University Medical Center	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
Parecoxib and Celecoxib	Parecoxib and Celecoxib	Peking Union Medical College Hospital	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (cyclooxygenase-2)
Parestat(generic parecoxib)	Parestat(generic parecoxib)	University of Malaya	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
Parecoxib Sodium/Valdecoxib	Parecoxib Sodium/Valdecoxib	Pfizer	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
Celecoxib 400 milligrams	Celecoxib 400 milligrams	Pfizer	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
parecoxib, valdecoxib, parecoxib and dexamethasone	parecoxib, valdecoxib, parecoxib and dexamethasone	Asker & Baerum Hospital	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
Celecoxib (Celebrex)	Celecoxib (Celebrex)	National Eye Institute (NEI)	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective COX-2 inhibitor (coxib) class)

Pfizer · 4 drugs in this class
Organon and Co · 2 drugs in this class
Laboratorios Silanes S.A. de C.V. · 2 drugs in this class
University of Malaya · 2 drugs in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National Eye Institute (NEI) · 1 drug in this class
Novartis · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
Radboud University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etoricoxib (Arcoxia) — Competitive Intelligence Brief. https://druglandscape.com/ci/etoricoxib-arcoxia. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing